[1] Merck’s Index, Nachtrag 1930. Verlag von E. Merck, Darmstadt. 14 Seiten[J]. Archiv der Pharmazie, 1930, 268 6: 444-445. DOI:
10.1002/ardp.19302680608[2] MARK J MILLAN. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.[J]. Journal of Pharmacology and Experimental Therapeutics, 2002, 303 2: 791-804. DOI:
10.1124/jpet.102.039867[3] EDNA GRÜNBLATT DSC (STUDENT). Apomorphine protects against MPTP-induced neurotoxicity in mice[J]. Movement Disorders, 2001, 14 4: 612-618. DOI:
10.1002/1531-8257(199907)14:4<612::aid-mds1010>3.0.co;2-6[4] MANON AUFFRET . Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations[J]. Journal of the Neurological Sciences, 2017, 372: Pages 279-287. DOI:
10.1016/j.jns.2016.11.080[5] PETER JENNER Regina K. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease[J]. Parkinsonism & related disorders, 2016, 33: Pages S13-S21. DOI:
10.1016/j.parkreldis.2016.12.003